Intravenous Milrinone is the Recommended Therapy
When inhaled nitric oxide (iNO) is unavailable for a term or near-term newborn with echocardiographically confirmed PPHN and an oxygenation index greater than 25, intravenous milrinone is the most reasonable intravenous therapy based on current guidelines. 1
Guideline-Based Recommendation
The 2015 AHA/ATS Pediatric Pulmonary Hypertension Guidelines specifically address this scenario and state that intravenous milrinone is reasonable in infants with PPHN and signs of left ventricular (LV) dysfunction (Class IIa; Level of Evidence B) 1. While the guideline frames this recommendation around LV dysfunction, this is particularly relevant because:
- Many infants with severe PPHN (OI >25) have concurrent cardiac dysfunction
- Milrinone provides both pulmonary vasodilation AND inotropic support
- It works through a nitric oxide-independent mechanism, making it suitable when iNO is unavailable
Why Milrinone Over Other Options
The guidelines also mention sildenafil and inhaled prostacyclin analogs, but these are specifically recommended as adjunctive therapy for infants refractory to iNO 1—meaning they're positioned as add-ons when iNO fails, not as primary alternatives when iNO is unavailable.
Milrinone's advantages in this context:
- Rapid onset: Research shows significant OI reduction within 24 hours of initiation 2
- Dual mechanism: Provides pulmonary vasodilation plus cardiac inotropic support 2
- Proven efficacy: In neonates with severe PPHN (OI >20) who failed iNO, milrinone reduced OI from 28.1 to 8.0 within 24 hours (P < .001) 2
- Hemodynamic stability: Does not cause systemic hypotension; actually trends toward improved blood pressure 2
Practical Implementation Algorithm
Starting milrinone when iNO is unavailable:
- Confirm diagnosis: Echocardiographic evidence of PPHN with right-to-left shunting
- Assess cardiac function: Look specifically for LV dysfunction on echo (strengthens indication)
- Loading dose: Consider 50 mcg/kg over 30-60 minutes (though some centers omit this to avoid hypotension)
- Maintenance infusion: Start at 0.33-0.5 mcg/kg/min
- Monitor closely: Blood pressure, heart rate, oxygenation every 15-30 minutes initially
- Titrate: Can increase to 0.75-1.0 mcg/kg/min based on response
- Expect response: Should see OI improvement within 4-24 hours 2
Critical Caveats and Monitoring
Watch for hypotension: While less common than with other vasodilators, dose adjustment or brief vasoactive support may be needed 3. This is manageable and should not deter use.
Extremely preterm infants: Exercise particular caution in very preterm neonates (<28 weeks), as milrinone's vasodilatory effects may increase risk of intraventricular hemorrhage 3. However, your patient is term/near-term, so this is less concerning.
Platelet effects: Milrinone has mild antiplatelet properties—monitor for bleeding, especially if coagulopathy present 3.
Alternative Considerations
If milrinone is also unavailable or contraindicated:
- Intravenous sildenafil: Demonstrated safety and efficacy in PPHN with OI >15, with significant OI improvement within 4 hours 4. However, this requires careful dose escalation and monitoring.
- Intravenous epoprostenol (prostacyclin): Shows rapid OI reduction in iNO-refractory cases 5, but requires specialized delivery systems and has higher risk of systemic hypotension.
The Bottom Line
Intravenous milrinone is your best option when iNO is unavailable for severe PPHN (OI >25). It has the strongest guideline support as a standalone therapy (Class IIa), works through a complementary mechanism, provides both pulmonary and cardiac benefits, and has demonstrated clinical efficacy in this exact population. Start at 0.33-0.5 mcg/kg/min after confirming the diagnosis with echocardiography, monitor hemodynamics closely, and expect oxygenation improvement within 24 hours. If the infant fails to respond or deteriorates, prepare for ECMO transfer, as this is indicated for severe PH refractory to medical management 1.